BioDelivery Sciences International, Inc. (NASDAQ:BDSI) specialty pharmaceutical firm, is reporting third quarter earnings results on Thursday 5th November 2020, before market open.
The consensus estimates from Thomson Reuters are income of $ 0.05 per share from $ 39.35 million in revenue.
For the full year, analysts predict revenues of $ 155.73 million, while looking forward to income of $ 0.17 per share.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 165.00 million ~ $ 175.00 million
Click Here For More Historical Outlooks Of BioDelivery Sciences International, Inc.
Previous Quarter Performance
BioDelivery Sciences International, Inc. reported income for the second quarter of $ 0.09 per share, from the revenue of $ 36.58 million. The quarterly revenues extended 47.98 percent compared with the same quarter last year. Street analysts expected BioDelivery Sciences International, Inc. to report income of $ 0.04 per share on revenue of $ 36.44 million for the second quarter. The bottom line results beat street analysts by $ 0.05 or 125.00 percent, at the same time, top line results outshined analysts by $ 0.14 million or 0.38 percent.
Stock Performance
Shares of BioDelivery Sciences International, Inc. traded up $ 0.13 or 3.90 percent on Wednesday, reaching $ 3.46 with volume of 637.20 thousand shares. BioDelivery Sciences International, Inc. has traded high as $ 3.48 and has cracked $ 3.31 on the downward trend
The closing price of $ 3.46, representing a 16.84 % increase from the 52 week low of $ 2.85 and a 53.81 % decrease over the 52 week high of $ 7.21.
The company has a market capital of $ 349.23 million and is part of the Healthcare sector and Biotechnology industry.
Conference Call
BioDelivery Sciences International, Inc. will be hosting a conference call at 8:30 AM eastern time on 5th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.bdsi.com
BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company provides its products based on its patented BioErodible MucoAdhesive drug-delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug-delivery technologies. It offers BELBUCA, a buprenorphine buccal film for the treatment of chronic pain; BUNAVAIL, a buprenorphine and naloxone buccal film to treat opioid dependence; and ONSOLIS, a fentanyl buccal soluble film for the management of breakthrough pain in opioid tolerant adult patients with cancer.
